The Trump administration on Wednesday (Feb. 19) filed its first brief in the Third Circuit Court of Appeals, defending Medicare’s drug price negotiation program against a myriad of allegations of unconstitutionality from the drug industry -- establishing that although the drug industry hopes to work with President Donald Trump on revising and limiting the scope of the price-setting mechanism, the administration may not be on the same page.